Genetic Technologies Limited (ADR)  

(Public, NASDAQ:GENE)   Watch this stock  
Find more results for GENE
0.379
+0.021 (5.87%)
Dec 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.34 - 0.38
52 week 0.31 - 2.41
Open 0.35
Vol / Avg. 166,362.00/460,004.00
Mkt cap 9.98M
P/E     -
Div/yield     -
EPS -0.44
Shares 613.92M
Beta 0.43
Inst. own 0%
Sep 29, 2014
Genetic Technologies Ltd Extraordinary Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin -197.34% -222.04%
Operating margin -197.34% -222.04%
EBITD margin - -207.62%
Return on average assets -91.44% -134.69%
Return on average equity -220.18% -271.26%
Employees 64 -
CDP Score - -

Address

60-66 Hanover Street, Fitzroy
Fitzroy, VIC 3065
Australia
+61-3-84127000 (Phone)
+61-3-84127040 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Genetic Technologies Limited (GTG) is engaged the provision of genetic testing services. The Company also conducts out-licensing program in respect of its non-coding deoxyribonucleic acid technology and supports a late-stage research project. The Company operates in three segments: Operations, Licensing and Research. The principal geographic segments of the Company include Australia, with the Company�s headquarters being located in Melbourne in the State of Victoria. The Operations segment includes the provision of a range of genetic testing services. The Licensing segment includes the out-licensing of the Group�s non-coding technology. The Research segment includes the undertaking of a range of research and development projects in the field of genetics and related areas. During the fiscal year ended June 30, 2012, the Company launched its new, predictive risk test, BREVAGen. BREVAGen is the clinically validated breast cancer predictive risk assessment tool.

Officers and directors

Alison J. Mew Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Eutillio Buccilli Chief Financial Officer, Chief Operating Officer
Bio & Compensation  - Reuters
Mark Ostrowski President of Phenogen Sciences Inc
Age: 50
Bio & Compensation  - Reuters
Richard Allman Ph.D Scientific Director
Age: 53
Bio & Compensation  - Reuters
M. Luisa Ashdown Director of Global Licensing and Intellectual Property
Age: 57
Bio & Compensation  - Reuters
Diana Newport Quality and Business Operations Director
Age: 56
Bio & Compensation  - Reuters
Malcolm Roy Brandon Ph.D. Non-Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Grahame James Leonard Director
Bio & Compensation  - Reuters
Paul Alexander Kasian Non-Executive Director
Bio & Compensation  - Reuters
David Noel Carter Non-Executive Independent Director
Age: 52
Bio & Compensation  - Reuters